BlossomHill to Accelerate BH-30643 Clinical Trials with $111.7 Million IPO
Targeting the C797S Resistance Market with IPO
BlossomHill Therapeutics is pursuing an initial public offering (IPO) of up to $111.7 million to list on Nasdaq as BLSM. The proceeds will be used for the global Phase 1/2 SOLARA trial of its oral small molecule candidate BH-30643, a potential pivotal Phase 2 trial, the Phase 1 trial of CLK inhibitor BH-30236, and the preparation of an Investigational New Drug (IND) application for pan-KRAS inhibitor BH-501284. Despite having $116 million in cash as of March 31, 2026, and cumulative funding of $257.2 million, the company notes the risks associated with being a continuing concern, indicating that this offering is primarily aimed at securing capital for key clinical milestones rather than expanding the scope of research.
Differentiation Targeting Tagrisso Resistance
BH-30643 is a non-covalent, mutation-selective OMNI-EGFR tyrosine kinase inhibitor (TKI) in Phase 1/2 clinical development, with no brand name yet. AstraZeneca's (AZN) Tagrisso (osimertinib) targets EGFR and, after FDA approval on November 13, 2015, EMA approval on February 2, 2016, and PMDA approval in Japan on March 28, 2016, has become the market standard. However, the C797S mutation prevents the covalent binding of osimertinib, and the design of BH-30643, which does not rely on this residue, provides a direct biological rationale for its use in subsequent treatments.
Promising Early Efficacy, but Limited Validation Period
As of May 20, 2026, the overall response rate (ORR) in the C797S target population was 53% (8/15) in the first-line setting and 42% (8/19) in the post-treatment setting, with a median follow-up of 4.2 months. Among the 22 patients with detectable C797S at baseline, 19 (86%) showed circulating tumor DNA (ctDNA) clearance, and 32 of the 44 patients overall (73%) were still receiving treatment at the data cutoff. While the direction of the signal is strong, the inclusion of unconfirmed responses and the short follow-up period mean that the FDA Phase 1 meeting in the fourth quarter of 2026 and the subsequent potential pivotal Phase 2 trial design will be key validation points for the company's valuation.
Large Market and Intense Competition
The global advanced progressive EGFR-TKI non-small cell lung cancer market was estimated at $7.93 billion in 2025, with Tagrisso accounting for $7.254 billion in sales in 2025. In the first-line setting, Johnson & Johnson's (JNJ) Rybrevant (amivantamab, an EGFR/MET inhibitor) and Lazcluze (lazertinib, an EGFR inhibitor) combination therapy are competing, while in the post-treatment setting, Datroway (datopotamab deruxtecan, a TROP2-targeted ADC), platinum chemotherapy, and Black Diamond Therapeutics' (BDTX) BDTX-1535 and Blueprint Medicines' BLU-945 series are being compared. Therefore, BH-30643 needs to demonstrate superior efficacy and safety as an oral monotherapy in C797S resistance to secure a commercial position, rather than simply being a Tagrisso alternative.
The $111.7 million IPO is a financing event that will advance the Phase 1/2 BH-30643 trial to a potential pivotal Phase 2 trial and bolster the company's cash reserves, which were $116 million as of March 31, 2026. If the ORR of 42-53% and ctDNA clearance rate of 86% are maintained in C797S patients, the company will be able to access the $7.93 billion advanced progressive EGFR-TKI market and the $7.254 billion in sales generated by Tagrisso. However, given the short median follow-up of 4.2 months, the durability of response and safety profile compared to BDTX-1535, BLU-945 series, Rybrevant/Lazcluze combination, and Datroway will be critical for long-term valuation. In the short term, IPO demand and the FDA meeting in the fourth quarter of 2026 will be key drivers of the stock price, and for R&D personnel, it means increased hiring demand for expertise in EGFR resistance clinical trials, biomarkers, and regulatory strategy.